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Abstract
Globally, contraceptive studies and their use are major challenges in the 
realm of public health. The ideal goal is to obtain a contraceptive method that 
is highly effective at minimizing unplanned pregnancies and nullifying the 
chance of contracting a sexually transmitted disease. Abstinence is currently 
the only way to attain such a dualistic goal, and while effective, it may not be 
suitable for sexually active individuals. While there is an abundance of method- 
specific information regarding the use of any one female contraceptive device, 
there is a paucity of resources that compare and contrast the advantages and 
disadvantages of such methods and enable an individual to optimize family 
planning. This paper attempts to address many of these topics by reviewing a 
multitude of U.S. Food and Drug Administration (FDA) approved contraceptive 
methods. This work is intentionally written towards educating medical students, 
educators and teachers at all levels of training with foundational knowledge 
regarding female contraception.
Keywords: Female contraceptive methods; Food and drug administration; 
Abstinence
the available options for their female partners. Increased awareness 
and understanding of hormonal contraception by men can increase 
access to these methods and improve adherence [8]. Despite these 
issues, contraceptives are used by 64% of married or in-union women 
globally [4]. Though a divisive issue, for the improvement of women’s 
health across the globe, it is imperative to improve understanding of 
the available methods. The proceeding discussion describes the use, 
risks, benefits, and costs of a number of female contraceptive methods. 
The aim of this review is to provide a comprehensive summary of 
these factors for each FDA approved contraceptive method as well as 
a discussion of the ethical implications of contraception visualized in 
the accompanying Quick Table.
Contraceptive Methods
Abstinence
Abstinence is a behavioral method of contraception in which 
individuals avoid engaging in any type of sexual activity altogether 
including but not limited to oral, anal, or vaginal intercourse. 
Abstinence is the only way a person can be completely certain of 
the prevention of pregnancy or infection with sexually transmitted 
diseases (STDs). Among older women, abstinence may reflect a 
genuine choice related to age. 10.4% of women between the ages of 
35 and 49 were likely to use abstinence as a contraceptive choice, 
whereas 8.3% and 8.1% of women ages 25-34 and 15-24 respectively 
practiced abstinence [9].
Abstinence is a reversible,  non-invasive,  free of financial cost 
method of contraception. This practice does not have any risks or 
medical/hormonal side effects. Abstinence-related risks occur when 
women decide to no longer abstain from sex. One of the most common 
failures of abstinence is failure to avoid sexual activity, which can lead 
to a lack of planning for alternative forms of contraception.
Introduction
In the United States, unplanned pregnancy continues to be a 
polarizing public health concern. Contraceptive methods remain 
a point of contention in American politics and public culture. At 
the same time, the United Nations Millennium Development Goals 
aim to increase access to reproductive health [1]. Between 2011 and 
2013, approximately 62% of women between ages 15 and 44 in the 
United States used a contraceptive method. The groups least likely to 
utilize contraceptive methods included women ages 15 to 24, Latinas, 
and those with a high school diploma or less [2]. While a myriad of 
options exist for the prevention of pregnancy and sexually transmitted 
infections (STIs), the population most drastically affected by unplanned 
pregnancy is younger women [3]. This is further complicated across 
the globe by lack of awareness and access to contraceptive methods. 
It is suggested that at least 10% of married women have an unmet 
need for family planning. In certain regions, this number is even 
higher, especially in sub-Saharan Africa and Oceania [4]. It has been 
demonstrated that discussion of sexual and reproductive issues with 
both families and students improves awareness and may increase 
utilization of methods to prevent pregnancy and sexually transmitted 
diseases, even in populations in the developing world [5]. Data 
from Switzerland, where contraception is less taboo, suggest that 
condom use is the most common method utilized by adolescents, 
particularly at first intercourse [6]. In the United States, health beliefs 
and social discussions about contraception have a major influence 
on health practices rather than methods based on evidence. In 
urban populations, it has been demonstrated that misconceptions 
regarding emergency contraceptive methods are largely gleaned 
from the opinions of individuals close to them [7]. Importantly, the 
limited use of female contraception is an issue shared by both male 
and female sexual partners. Generally, men lack knowledge regarding 
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This may cause some women to end periods of abstinence without 
having an alternative form of contraception [9]. There are no health 
contraindications associated with the use of abstinence as a form of 
contraception. If a woman believes that she will not be able to abstain 
from sex for extended periods of time, she should not consider 
abstinence as her primary form of birth control [10]. Consideration 
should also be given to psychological factors, such as confidentiality 
and cultural factors that may affect the choice of abstinence as a 
primary modality of contraception.
Copper T intrauterine device
The Copper T Intrauterine Device (IUD) is a reversible, non- 
hormone based method of female contraception with a unique ability 
to work in an efficient manner for a prolonged period of time [11]. 
As shown in Figure 1, the Copper T IUD is a T-shaped polyethylene 
flexible structure containing 380 mm of copper wire situated 
throughout its stem and arms [12].
The Copper T IUD is installed into the uterus [12]. The 
insertion process tends to be uncomplicated, with the most 
common complication from insertion being perforation. For the 
Copper T-380A IUD, perforation rates for insertion occur at a rate 
of 1.5 per 1,000 [14]. Once inserted, the Copper T IUD impedes 
fertilization through the virulent effects that copper has on the sperm 
and ovum, and by acting as a physical barrier to the sperm’s voyage 
towards the egg [11]. In multiple trials, the Copper T IUD has proven 
to be an effective form of female contraception, revealing the risk of 
pregnancy while utilizing this device is 0.6% [15].
Though Copper IUDs have been in production for decades, in the 
1980s, IUDs were criticized due to their inability to prevent sexually 
transmitted diseases, causing a decline in their utilization [16]. In the 
early history of the copper T IUD, liability claims negatively affected 
the use of the device and eventually manufacturers were forced to 
remove them off of the market. Eventually, one of the removed 
copper T IUDs was reinstituted into the market [16]. Copper T 
IUDs are a very practical form of contraception. After the insertion 
of the Copper T there is no need for patient follow up with her 
healthcare professional for dosing administration as seen with most 
hormone based methods [11]. The Copper T IUD becomes effective 
immediately after insertion. More so, being hormone free makes this 
method safe for use for women with breast cancer, hypertension, 
uncontrolled diabetes mellitus, and thromboembolic disease [11].
The uninterrupted use of the Copper T IUD has been approved 
for 10 years, meaning that a woman utilizing this Copper T IUD can 
keep it inserted for 10 years and it will work successfully for up to 12 
years [11]. As previously mentioned, the Copper T IUD is reversible, 
which is made possible through the use of a string attached to the 
base of the T frame facilitates the process of removal and reversibility. 
After removal, the woman physiologically returns to fertility and the 
processes of ovulation typically occur anywhere from  10-14  days 
after removal. The use of Copper T IUD has possible side effects, 
including escalated bleeding during menstrual cycles, cramping and 
increased menstrual pains [11]. Although, in many patients these side 
effect diminish over time, they might vary in length depending on 
the age of the patient. The most profound reason for the removal of 
Copper IUDs is attributed to excessive vaginal bleeding which may 
result due to improper sizing of the device relative to the patient’s 
uterine cavity [16]. There are several other contraindications and side 
effects summarized in Table 1. Studies have specifically shown that 
the Copper T 380A IUD is one of the most affordable methods of 
contraception with the  5-year  cost of use estimated at $1,678 USD 
without insurance [17].
Levonorgestrel IUD
Intrauterine devices containing Levonorgestrel are an effective 
and reversible form of long term contraception. Levonorgestrel is a 
synthetic form of progesterone used in many oral contraceptives and 
contraceptive implants. The Levonorgestrel intrauterine device, as 
shown in Figure 2, delivers a dose of Levonorgestrel daily for up to 
five years [18].
Levonorgestrel physiologically functions by restricting the growth 
Figure 1: Intrauterine device [13].
Figure 2: Levonorgestrel intrauterine device [19].
Figure 3: Female contraceptive implant [23].
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Technique Usage Adverse reactions Length of Action
Invasive- 
ness
Rever- 
sibility Cost ($ - $$$)
Patient 
Considerations Important Information
Abstinence
Non-
participation 
of vaginal 
intercourse
No adverse reactions 
known. Variable Non-Invasive Reversible No cost.
This method has 
been proven to work 
best in young, single 
women and women 
reaching the end of 
their reproductive 
years. This method 
also works better 
among educated 
couples than less 
educated couples [9].
Anyone can practice 
abstinence. There is 
no link 
between religious 
affiliation and an 
individual's decision to 
remain abstinent [9].
Copper T 
IUD
Copper T IUD 
is installed into 
the uterus [12]. 
Once 
inserted, the 
Copper T 
IUD impedes 
fertilization 
through killing 
both sperm and 
egg cells while 
physically 
obstructing the 
sperm’s voyage 
towards the egg 
[11].
Escalated bleeding 
during menstrual 
cycles and increased 
menstrual pains are 
common. Very 
rare reports including 
expulsion of the IUD, 
pelvic inflammatory 
disease, or ruptures 
during the insertion 
process [11].  
Studies 
have identified a rare 
link between Copper 
T IUD and Human 
Papillomavirus 
(HPV) [113].
The 
uninterrupted 
use of the 
Copper T 
IUD has been 
approved for 
10 years [11]. 
Invasive - 
requires a 
procedure 
conducted by 
a healthcare 
professional 
[11].
Reversible 
[11].
Estimated 
cost is $1,678 
without 
insurance 
[114].
$$$
This method of 
contraception is non-
hormone based. It is 
safe for women with 
breast cancer, 
hypertension, 
uncontrolled 
diabetes mellitus, 
and thromboembolic 
disease [11].
The probability of 
pregnancy while 
utilizing this device is 
0.6% [15].
Levonor- 
getsterel 
IUD
The device is 
implanted every 
5 years [17].
Miscarriage, preterm 
birth, possible 
infection, pelvic 
inflammatory 
disease, possible 
development of 
ovarian cysts [17]. 
Less serious but 
possible side effects 
include nausea, 
mood changes, 
weight gain and 
dizziness [17].
The 
contraceptive 
effect of the 
IUD lasts for 
up to 5 years 
after device 
placement [17].
Invasive as 
the device is 
inserted in the 
uterus [17].
Reversible 
[17]. 
Approximately 
$1,646 every 5 
years [20].
$$$
This method is 
convenient for 
women seeking 
a long term 
contraceptive 
method. The 
levonorgestrel 
IUD should not be 
used by patients 
who experience 
unexplained vaginal 
bleeding or in 
patients who have 
been diagnosed 
with chlamydia or 
gonorrhea [19]. 
This intrauterine device 
is 99% effective [17]. 
Implant
The implant 
can be inserted 
every 3-5 years 
[25].
Potential risk 
of bruising and 
infection at the site 
of injection. 
Abdominal, back, or 
breast pain, irregular 
vaginal bleeding, 
headaches, nausea, 
weight gain, ovarian 
cysts [27].
Depending on 
the model and 
dosage of 
progestin, the 
implant can be 
effective for 3-5 
years [23].
Invasive as 
it is a small 
flexible rod 
that is inserted 
under the skin 
of the upper 
arm [21].
Reversible 
[21].
$0-$800, 
varies with 
insurance [21].
$$$
Useful for patients 
desiring a long-
lasting contraceptive 
method. The implant 
cannot be 
inserted in pregnant 
women and should 
not be used by 
women with a history 
of breast cancer, 
liver disease, blood 
clots, or irregular 
vaginal bleeding [23].
Successfully prevents 
more than 99% of 
pregnancies. It doesn't 
protect against STIs 
[25]. 
Injection
Injections 
are typically 
repeated 
every one to 
three months 
depending on 
the hormone 
being used [32]. 
Amenorrhoea, heavy 
bleeding, or frequent 
bleeding, weight 
gain, and decreased 
bone mineral density 
are among the 
most common side 
effects [32]. Many 
side effects are 
not harmful and 
are reduced 12 to 
18 months after 
discontinued use 
[33].
Depending on 
the hormone 
being used, 
injections can 
be 
effective for 
one month 
(Lunelle), eight 
weeks 
(NET-EN), or 
three months 
(DMPA) [32].
Minimally 
invasive with 
slight 
discomfort 
at the site of 
injection [16].
Reversible 
with delay.
Ovulation 
may take 
from 
14 weeks to 
18 months to 
resume [115].
$50 - $60 per 
injection, $0 
with insurance 
[36].
$-$$
Injections are safe for 
most women and can 
be used by women 
of reproductive age. 
Women who are 
pregnant as well as 
those with severe 
hypertension or 
vascular disease, 
cancer, and liver 
disease should 
not use injectable 
contraceptives [30, 
34].
Table 1: Female contraceptive – quick table guide.
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Combined 
Oral 
Contrace-
ptives
Taken at the 
same time daily 
[39].
Venous 
thromboembolism, 
ypertension, stroke, 
myocardial infarction 
[40].
Each pill lasts 
about 24 hours 
- taken 
continually oral 
contraceptives 
are effective 
until 
discontinued 
[40].
Non- invasive
Reversible 
with timedelay 
[39].
$30-50 per 
monthly 
pack, $0 with 
insurance [39].
$$
This method of 
contraception is 
usually prescribed 
to adolescent and 
young women. 
However, combined 
oral contraceptives 
can be used by any 
healthy reproductive 
aged female. 
Women who are 
heavy smokers, 
have sickle cell 
disease, previous 
cardiovascular 
illnesses and 
those who have 
gallbladder disease 
should avoid taking 
combined oral 
contraceptives due to 
increased risk of side 
effects [40].  
Progestin 
Only
Progestin only 
pills should be 
taken at the 
same time each 
day and have a 
three 
hour window 
for maximum 
effectiveness 
[34].  
Irregular bleeding, 
headaches, nausea, 
breast tenderness, 
acne, weight gain to 
a lesser degree, 
formation of ovarian 
cysts, reduced 
efficacy from other 
medications 
processed by the 
liver, higher rates of 
ectopic pregnancies 
[30,42].
This 
contraceptive 
method is 
effective 
until dis- 
continuation 
[30].
Non-invasive 
form of 
contraception 
[19].
Reversible 
with time 
delay [45]. 
After 24-
hours 
without the 
pill, cervical 
mucus 
normalizes 
[37].
$20 - $50, 
varies with 
insurance [46].
$$
Women 
contraindicated with 
estrogen based 
contraceptives, 
those suffering 
with migraines or 
smokers over the 
age of 35, benefit 
from this 
method [42]. Women 
should not use if 
they have acute 
liver disease, breast 
cancer, pregnancy, 
genital bleeding, 
or cardiovascular 
disease [30].
Progestin-only 
contraceptive pills 
were developed as an 
alternative to estrogen 
in combination 
oral contraceptives 
which led to increased 
risk of 
venousthrom- 
boembolytic events 
[43].
Hormonal 
Vaginal Ring
The vaginal 
ring is manually 
inserted into the 
vagina and worn 
3 weeks and 
then taken out 
for 7 
days to allow 
endometrial 
shedding [30].
Vaginal secretion, 
breast tenderness, 
headache, nausea, 
vaginitis, coital 
issues, foreign body 
sensation, and ring 
expulsion [30, 34].
Effective until 
discontinuation. 
Efficacy is 
reduced if a 
new ring 
is not utilized 
within 24 hours 
after the 7-day 
shedding 
period [48]. 
Moderately 
invasive 
through 
insertion into 
the vagina 
[49].
Reversible 
with time 
delay post-
disconti- 
nuation [49].
$0 to $80 [51].
$-$$
Women should not 
use this method if 
they smoke over the 
age of 35 and have 
coronary artery 
disease, diabetes, 
Lupus, severe 
hypertension, 
thromboembolic 
disorders, known 
pregnancy, or 
localized migraines 
[30].
Birth Control 
Sponge
Sponge 
placed before 
intercourse [53].
Toxic shock 
syndrome, vaginitis, 
irritation [57]. 
Can be used 
as a form of 
contraception 
for up to 24 
hours after 
sponge is 
inserted [55]. 
Somewhat 
invasive form 
of 
contraception 
[53]. 
Reversible. $
This method of 
contraception can be 
used by all women. 
However it is not as 
effective as the 
other forms of 
contraception. 
For safety, it is 
advised that the 
sponge not be used 
during menses or 
puerperium [57].
Available over the 
counter [58].
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Diaphragm 
or Cervical 
Cap
Impedes the 
sperm from 
making its way 
into the  
cervix by being 
positioned 
in a manner 
that covers the 
cervix. This is 
considered an 
invasive 
method of 
contraception 
[57,60].
Applications of 
diaphragms with 
spermicides may 
increase the 
probability of urinary 
tract infections [57].
Advised time 
limit of usage 
of 1-year for 
a diaphragm. 
With 
regular 
maintenance, 
lifespan can be 
stretched to 
two years [57].
 Invasive 
method of 
contraception 
[60].
Reversible 
[57]. $
Indications for the 
use of diaphragms 
are made if the 
patient is unable to 
use hormonal 
contraceptives, if the 
patient is 6 weeks 
postpartum, and 
if the patient has 
rare sexual activity 
among other factors 
[57].
There are in fact 
allegations of a type of 
diaphragm made from 
silicone 
elastomer that has the 
unique ability 
to release an 
administered dose of 
spermicide, 
Nonoxynol-9 (N-9) [62].
Female 
Condom
Every time 
there is sexual 
intercourse [64] 
Allergies, not always 
100% effective
Whilst having 
sex
Not very 
invasive, easy 
to apply and 
remove [64]
Reversible 
[64].
$6 for 3 
condoms, 
[66]. $
Good for both 
partners to avoid 
pregnancy and 
STDs [66]
Over-the-counter, more 
effective than male 
condoms [68]
Spermicide
Chemical agent 
that impair the 
sperm’s mobility 
by disabling the 
sperm to 
move into the 
vagina or killing 
the sperm cell 
[59].
May cause a higher 
risk urinary tract 
infections (UTI) from 
women that use 
spermicides as a 
form of 
contraception vs. 
those that apply 
distinct contraception 
methods 
[70]. May cause 
irritations and 
allergic reactions to 
the woman or her 
counterpart [59].
Typically, 
spermicides 
should be left 
on for 6-8 
hours after 
intercourse in 
order to work 
efficiently [69].
Somewhat 
invasive form 
of 
contraception  
[59].
Reversible 
[59].
Reasonably 
priced and 
affordable [70].
$
Good for any 
woman who is 
unable to utilize 
hormonal forms of 
contraception [59].
The efficiency is 
increased when used 
with barrier 
devices like 
diaphragms or cervical 
caps [62].
Natural 
Planning or 
Fertility 
Awareness
Avoid sex during 
fertile days of 
the month.
No adverse reactions 
known.
Performed 
monthly 
during fertile 
days of the 
menstrual cycle 
[71].
Non-invasive 
form of 
contraception.
Reversible.
Around $20 for 
thermometer 
and calendar/
fertility 
awareness 
chart.
$
The method should 
work similarly for all 
women. 
In the US, it is more 
effective among 
white women 
between 19 and 29 
years of age who are 
in long-term, stable 
relationships, and 
have high school 
education or higher 
[72].
This method is 
associated with a lower 
incidence of 
induced abortion in the 
US, and with a divorce 
rate lower than the 
general 
American population 
[72].
Tubal 
Ligation
Before or after a 
pregnancy.
Not 100% effective. 
Pregnancy remains 
a possibility in 5 
out of 
1000 women after a 
year, and in 13 out of 
1000 women after 5 
years [75].
Permanent 
length of action 
after 
contraceptive 
method is 
performed.
Invasive 
form of 
contraception. 
Surgery is 
performed, 
most of the 
time via 
laparoscopy 
[75].
Reversible 
with tubal 
anasto- 
mosis. May 
have 
therapeutic 
limitations.  
[77].
Costs range 
from $0 to 
$6,000, varies 
with insurance 
[79]. 
$$-$$$
Best for older 
women and women 
who already have 
children.
Associated with a 
lower incidence, stage, 
and 
mortality of endometrial 
and ovarian 
carcinomas [80].
Trans- 
cervical 
Sterili- 
zation
Before or after 
a pregnancy. 
Method 
prevents 
pregnancy and 
doesn't protect 
against STIs.
Approximately 8% 
of first attempts 
at procedure are 
unsuccessful [89]. 
Procedure may 
cause pain, 
dizziness, nausea, or 
light bleeding. 
Potential risk of 
ectopic pregnancy 
or the insert moving 
out of place (can be 
removed if needed) 
[90].
After the 
occlusion is 
confirmed, 
length of action 
is permanent 
[83].
Invasive as 
the procedure 
is 
performed 
hystero- 
scopically 
[87].
Irreversible
$0-$6,000, 
varies with 
insurance [92]. 
$$-$$$
Mostly a permanent 
method of 
contraceptive. 
Suggested for older 
women.
Not recommended 
for women that are:  
- Currently pregnant, 
- Delivered 
or terminated 
pregnancy 6 weeks 
prior to insertion
- Recent pelvic 
infection
- Proximal tubal 
occlusion- 
Currently taking 
immunosuppressants 
- Have a unicornuate 
uterus [91].
Prior to the complete 
occlusion, it suggested 
to use another method 
of 
contraceptives to 
prevent pregnancy 
[87].
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of the endometrium. The thinning of the endometrium creates a 
harsh environment unsuitable for the blastocyst implantation [20]. 
Intrauterine device placement is a rather invasive procedure, as the 
device is inserted into the uterus through the vagina and cervix [18]. 
The levonorgestrel IUD is 99 % effective. The 5-year cost without 
insurance estimate of using the Levonorgestrel uterine device is about 
$1,646 USD [21]. Some side effects associated with the implantation 
of the intrauterine device include nausea, mood changes, and changes 
in bleeding patterns, acne, dizziness, headaches, weight gain and 
the possible development of ovarian cysts. Other rare but possible 
complications related with the use intrauterine devices include the 
perforation of the wall of the uterus, miscarriage, preterm birth and 
possible infection [18]. The device should not be used by patients who 
exhibit unexplained vaginal bleeding and in patients who have been 
diagnosed with chlamydia or gonorrhea since IUD insertion can lead 
to the development of pelvic inflammatory disease (PID) [20]. 
Hormone implant-extrauterine
A non-intrauterine female hormone based contraceptive implant 
consists of a  small bendable rod approximately 4 cm in length that 
is inserted into a woman’s upper arm subdermally, just under the 
skin, as seen in Figure 3. Similar to a levonorgestrel IUD, the implant 
releases progestin, a hormone that can be used to prevent pregnancy 
[22]. 
Physiologically, Progestin acts to thicken the mucus of the cervix 
which impedes cervical sperm transport. The implant differs from 
the levonorgestrel IUD in that high doses of synthetic progestin 
can prevent ovulation [22]. The implant is effective for 3-5 years, 
depending on the product and model used [24]. The implant can be 
used by women of all ages. Less than 1% of women with an implant 
become pregnant, rendering this a highly effective method [25]. It 
cannot prevent against sexually transmitted infections (STIs), so it is 
commonly used alongside methods that prevent STIs [26]. 
The implant is inserted by a trained health care provider as part 
of a routine in-office procedure [22]. The upper arm is cleaned and an 
anesthetic is used to numb the area, after which a needle applicator is 
used to insert the device(s). The site heals within 3-5 days. In order for 
the implant to be removed, a local anesthetic is used prior to making a 
small incision in the arm. The implant is then pulled out. If desired, a 
new implant can be placed in the same location [27]. The implant can 
be removed any time during the 3-5 year effective period. Once the 
implant is removed, the female hormone cycle resumes normality. If 
one does not desire pregnancy, a new birth control method should be 
used immediately [22]. 
Although uncommon, bruising or infection in the area of the 
injection can occur. The implant may cause irregular vaginal bleeding 
as well as abdominal, back, or breast pain. There is also a risk of 
headaches, nausea, weight gain, or developing ovarian cysts [27]. It 
should not be inserted during pregnancy. The implant also should 
not be used in women that have history of breast cancer, liver disease, 
blood clots, or irregular vaginal bleeding [24]. Depending on both 
the brand used and insurance, the implant can cost up to $800 per 
insertion and up to $300 for removal (USD) [22]. 
Depot injection 
Injectable contraceptives are shots of the progestin hormone, 
specifically depot medroxyprogesterone acetate (DMPA), injected 
intramuscularly or subcutaneously in the arm or the buttocks 
[28]. Figure 4 illustrates the most widely used form of injectable 
contraceptives, Depo-Provera.
Medroxyprogesterone acetate (MPA or Lunelle), 
Norethisteroneenantate (NET-EN), and Mesygina are less commonly 
used injectables which are administered in a similar manner [29]. The 
main function of the injectable method is to prevent ovulation by 
altering the endometrial lining by blocking the action of luteinizing 
hormone [30]. It is important to note that this method does not 
protect against STDs. 
Emergency 
Contra- 
ception
1-5 days 
after sexual 
intercourse [96].
Headache, nausea, 
and low possibility of 
pelvic inflammatory 
disease [97,98].
Once after 
sexual 
intercourse 
[93].
Non invasive, 
just taking of a 
pill [93].
Irreversible
$50 purchased 
over-
thecounter, 
less if covered 
by insurance 
[97]. 
$$
Good for female 
trying to avoid 
pregnancy after 
having sexual 
interaction [94].
Some work better 
than others and are 
highly time dependant. 
Mechanism- 
Preventing sperm 
to fertilize an egg. 
Not equivalent to the 
"abortion pill" [96].
Note: USD = U.S. 
$: $0 - 20; $$: $20-100. 
Dollar $$$: >$100.
Figure 4: The Depo-Provera contraceptive injection [29].
Figure 5: Combined oral contraceptive pack [38].
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DMPA has been available in other countries like Indonesia, 
Mexico, and Thailand since the 1960s. Originally approved in the 
United States for the treatment of endometriosis and habitual 
abortion in 1960, DMPA was later approved for contraceptive use 
in 1992 after an extensive study published by the World Health 
Organization (WHO). This study revealed that DMPA led to no 
significant increases in breast or uterine cancers.  The injection is 
composed of an aqueous solution containing suspended micro-
crystals. Other injectables are widely used outside of the United States 
due to ease of continuity [31].
DMPA must be repeated every twelve weeks or three months at 
150 mg/1 mL while NET-EN must be repeated every eight weeks at 
200 mg/1 mL. Lunelle is repeated monthly [32]. The micro-crystals 
containing the hormones are in solution and slowly released into 
the blood over time. With every injection, there is an increase in 
progestrogen levels during the first 24 to 48 hours followed by a steady 
decline in the following weeks [33]. After discontinuation, it may take 
up to 12 to 18 months for contraceptive effects to wane [34,35]. 
Injectable contraceptives are minimally invasive with slight 
discomfort at the site of injection [30]. DMPA is completely reversible 
and may be used by women of all ages. Injectable contraceptives are 
considered a method of long-acting reversible contraception. After 
discontinuing treatment, ovulation may take 14 weeks to 18 months to 
return [35]. Some common side effects include bleeding abnormalities 
such as amenorrhea (absence of menstrual periods), heavy bleeding, 
or frequent bleeding. Other effects include weight gain and decreased 
bone mineral density [32]. Many of these side effects are not harmful 
and are reduced 12 to 18 months after discontinuation [31, 33].
Injectable contraceptives are safe for most women. However, 
some contraindications exist among women who are pregnant and 
those with severe hypertension or vascular disease [30]. Women with 
diabetes can use injectable contraceptives, but this may lead to an 
adverse effect on glucose metabolism. Women with liver disease such 
as acute hepatitis, liver carcinoma, and liver cirrhosis generally should 
not use DMPA as it is metabolized in the liver. Women with breast 
cancer should also not use DMPA [34]. Injectable contraceptives are 
the most cost effective after one year of use [35]. Without insurance, 
the shot alone - excluding the cost of physician consultation charges 
ranges from $50 - $60 per injection. With insurance, the cost may be 
completely reduced to $0 [36].
Combined oral contraceptives
Combined oral contraceptives, more commonly known as birth 
control pills, contain a combination of two female hormones: estrogen 
and progestin [37]. Figure 5 illustrates a standard pill package for this 
method of contraception.
Progestin is associated with the majority of the contraceptive 
activity of the pill. The progestin component thickens the cervical 
mucus which makes it more difficult for sperm to enter the cervix 
leading to the uterus. It also suppresses the production of hormones 
that control ovulation. The estrogen component serves as a suppressor 
of hormones that cause ovulation [37]. If there is no ovulation, 
pregnancy cannot occur. Combined oral contraceptives should be 
taken at the same time daily. If taken exactly according to package 
directions only 3 out of 1000 women will become pregnant. Thus, 
combined oral contraceptives are 97% effective [39]. However, when 
used without complete adherence to instructions, there is a failure 
rate of 9%.
Potential side effects associated with combined oral 
contraceptives include an increased risk of cardiac problems such 
as venous thromboembolism, arterial thrombosis, myocardial 
infarction, hypertension a n d stroke. These risks are more likely 
to occur in women with a previous history of hypertension, heavy 
smoking, sickle cell disease, cardiovascular diseases, gallbladder 
disease, or have a pre-existing hypertension. Noncardiac associated 
side effects include migraines and esophageal reflux. Women who 
have a previous history of depression may experience worsening of 
their symptoms [40]. Combined oral contraceptives are a reversible 
and non-invasive form of contraception. Women who stop taking the 
oral contraceptive pill will have a two week delay in the resumption 
of ovulation. Brand named combined oral contraceptives usually 
cost around $50 USD monthly. However, there are generic options 
available which sell for around $30 per pack (USD). Many insurance 
providers do not cover the cost of combined oral contraceptives; 
however, some offer a co-pay option where the patient only pays a 
fraction of the cost [39].
Progestin only oral contraceptive
Progestin-only  contraceptive pills, also known as mini pills, 
contain 35%-75% of the progestin contained in combination pills and 
must be taken at the same time each day [30]. Figure 6 illustrates a 
standard 28-day progestin pill package.
Unlike combination pills, these do not contain estrogen. About 
9 out of 100 women become pregnant when using the pill correctly 
during the first year [34]. They function by reducing the amount 
of  follicle-stimulating  hormone (FSH) and luteinizing hormone 
(LH) while suppressing ovulation for about 50% of cycles [34]. In 
addition, they help to thicken cervical mucus which helps to prevent 
the penetration of sperm [30]. This method does not protect against 
STDs.
Progestin-only  contraceptive pills have been available as a 
method of birth control since the 1960s [42]. They were initially 
developed to avoid the high dosage of estrogen in combination oral 
contraceptives which led to increased risk of venous thromboembolic 
events. Estrogen dosages have been significantly reduced over the 
past few decades, but the development of  progestin-only  pills was 
Figure 6: Progestin birth control pills [41].
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promoted to reduce such risks [43]. Women contraindicated with 
estrogen based contraceptives, such as those suffering with migraines 
or smokers over the age of 35, have been able to benefit from this 
method [42]. According to the National Survey of Family Growth, 
approximately 0.4% or 250,000 women between the ages of 15 and 44 
currently use progestin-only pills [43].
Pills must be taken daily within the same  3-hour  window for 
maximum effectiveness [34,44]. After 48 hours, full effects occur in 
the cervical mucus [44].  Progestin-only  pills are  non-invasive  and 
taken orally [34]. This method of contraception is known as a short- 
acting hormonal method [45]. After a  24-hour  period without the 
pill, cervical mucus normalizes. The normal ovulation cycle returns 
faster for these women than those on the combination pill [37].
Possible risks associated with progestin-only pills include 
formation of ovarian cysts and reduced efficacy from other 
medications processed by the liver. Common side effects include 
irregular bleeding, headaches, nausea, breast tenderness, acne, 
and weight gain to a lesser degree [30]. Women using this method 
also have a higher rate of ectopic pregnancies compared to women 
that use other methods [42]. Absolute contraindications for this 
contraceptive method include acute liver disease, breast cancer, 
pregnancy, or genital bleeding [30]. A relative contraindication is 
current cardiovascular disease such as venous thromboembolism 
[42,43]. The cost of progestin-only pills typically range from $20-$50 
per month (USD) for those without insurance coverage. Those with 
insurance may have their prescription fully covered or may have a 
higher copay depending on the brand. Additional costs may include a 
visit to the physician and tests such as a pelvic exam which could range 
anywhere from $35 to $250 (USD) depending on insurance coverage. 
Some pharmacies and universities offer discounts on generic versions 
of these pills [46].
Hormonal vaginal ring
The hormonal vaginal contraceptive ring is a flexible device 
placed inside the vagina that releases a combination of the hormones 
estrogen and progestin. The ring is worn for 21 days taken out 
during menstruation. After menstruation, a new ring is inserted to 
begin the following cycle [30]. Figure 7 illustrates the proper method 
of self-inserting the vaginal ring after consultation with a healthcare 
provider.
Approximately 9 out of 100 women using this method become 
pregnant during their first year of use [47]. This method inhibits 
ovulation and alters the composition of the cervical mucus. 
Contraceptive rings offer the lowest dose of estrogen out of all 
combined contraceptives. It does not protect against transmission 
of STDs [30]. The contraceptive ring was developed as a means of 
delivery of a constant small dosage (about 120 mcg of etonogestrel 
and 15 mcg of ethinyl estradiol per day) over a sustained period of 
time due to low rates of continuity with oral contraceptives. The first 
studies conducted on this novel idea were published in the 1960s, 
and with time, new components were added and altered [48]. The 
ring, measuring about 54 mm in diameter, is currently made of the 
polymer ethylene vinyl acetate. The outermost layer is the portion that 
releases hormones evenly over time [30]. The most commonly used 
brand, Nuva Ring, was approved for contraceptive use in 2001 by the 
FDA [48]. For the ring to be effective, the device does not require a 
specific positioning in the vagina. However, it will be less likely to fall 
out the further back it is placed. The hormonal vaginal ring secretes 
hormones continually and is used for three weeks followed by a week- 
long period where it is withdrawn [49]. Efficacy is reduced if a new 
ring is not put into place within 24 hours after the 7-day period [58]. 
The hormonal vaginal ring is moderately invasive through insertion 
into the vagina. This may cause some discomfort for some women, 
and the device may be easily dislodged [54]. After discontinuation 
of the vaginal ring, all effects are rapidly reversible with ovulation 
resuming in as little as a few days or as long as a few months [49].
Typical side effects of the vaginal ring include increased vaginal 
secretion, breast tenderness, headache, nausea, and vaginitis [30]. Many 
of these effects are similar to those of other combined contraceptives. 
Effects and r isks specifically associated with this device include 
coital issues, foreign body sensation, and ring expulsion [30,34]. 
Vaginal rings are safe for most women of reproductive age. Absolute 
contraindications for this method are shared with all other forms 
of combination contraceptives including coronary artery disease, 
diabetes, Lupus, and severe hypertension. Relative contraindications 
include thromboembolic disorders, cigarette smoking in women over 
the age of 35, known pregnancy, and localized migraines [30]. Some 
studies reveal that this method may decrease total cholesterol [50]. 
The vaginal ring itself, available in one universal size, costs up to $80 
(USD) depending on insurance coverage. Additional costs associated 
with a physician visit and physical exams can range up to $250 (USD). 
Some clinics and drugstores offer to charge based on an individual’s 
income [51].
The birth control sponge, shown in Figure 8, is a type of 
contraception used in the birth canal. The sponge contains a 
spermicide to prevent fertilization. In addition to the spermicide, 
the sponge also has virucidal and bactericidal components that can 
Figure 7: How to insert a vaginal ring [47].
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potentially serve as protection from STDs [53]. Most birth control 
sponges contain  Nonoxynol-9,  which immobilizes sperm through 
the disruption of the sperm cell membrane. Findings show that 
this spermicide can impede diseases such as gonorrhea, chlamydial 
infection, candidiasis, genital herpes, syphilis, trichomoniasis and 
HIV [54]. However, it is highly advised that aside from the birth 
control sponge, other protection be used to prevent these diseases. 
The sponge can be used as a contraception method for up to 24 
hours. The birth control sponge was developed as an alternative to 
the contraceptive diaphragm [65]. This method of contraception 
is among the least effective, failing approximately 10% percent of 
the time [56]. However, some studies show that the sponge is only 
75% effective [57]. Possible risks that can occur when using the 
birth control sponge include pregnancy, irritation, discomfort and 
vaginitis. A rare side effect is toxic shock syndrome. It is advised 
that the sponge not be used during menses or during the six week 
period after childbirth [58]. The birth control sponge is available over 
the counter. This method of contraception is relatively inexpensive 
ranging from $10 to $15 (USD).
Diaphragm or cervical cap
The diaphragm is a method of female contraception that impedes 
sperm from entering the cervix, as shown in Figure 9 [59]. There 
are two kinds of contraceptive caps which are the diaphragm and 
the cervical cap [60]. Diaphragms tend to be larger in size than the 
cervical cap, about the size of the palm of the hand [60]. Cervical 
caps are much smaller, about the size of a small egg cup [60]. Use of 
the diaphragm is more common than that of the cervical cap. To use 
the diaphragm, a woman must situate the device in such a manner 
that it will barricade the sperm from reaching the cervix [60]. The 
majority of diaphragms are installed in a dome down method, but 
certain forms of diaphragms exist that can be placed in a dome up 
position [59]. The less common cervical cap has to be positioned 
directly on the cervix to detain the sperm from entering [60]. The 
preference between a cervical cap and the diaphragm are dependent 
on the woman, though typically women find it troublesome to keep 
the diaphragm in place due to their vaginal shape. For this reason, 
cervical cap use is more common in the United States [60].
Diaphragms are typified by their dome shape visualized in Figure 
9. They are flexible and made of silicone with a spring activated rim 
which serves to obstruct sperm from reaching the cervix [59]. The 
diaphragm is kept in place by these rims which may be a flat- spring 
rim, coil-spring rim, or an arcing-spring rim generating a seal around 
the vaginal wall [59]. The diaphragm is a non-hormonal method of 
contraception. Diaphragms are frequently used alongside spermicides, 
utilizing chemical contraceptives such as  Nonoxynol-9  to further 
facilitate and aid in the prevention of unwanted pregnancies [59]. 
When employing a diaphragm it is endorsed to apply two strips of 
spermicide on the superior surface of the diaphragm [59].
Current research and design initiatives are focused on a type of 
diaphragm made from silicone elastomer that has the unique ability 
to release an administered dose of spermicide,  Nonoxynol-9  (N-
9) [62]. For a patient to acquire a diaphragm, fitting must take place. 
The process of fitting is done through pelvic exam [59]. A diaphragm 
is a removable method of contraception [59]. Following the 
withdrawal of a diaphragm it must be rinsed in lukewarm water with 
soap and dried [59]. There is an advised time of use of one year for a 
diaphragm, but if properly maintained, this lifespan can be stretched 
to two years [59]. There may be a need to for a refitting postpartum, 
or if the patient has had a 15 pound change in weight, or following 
any gynecological procedures [59].
Indications for the use of diaphragms include inability to use 
hormonal contraceptives, postpartum status, and low frequency of 
sexual activity [59]. Contraindications for the use of a diaphragm 
include gynecological abnormalities, insufficient vaginal muscle- 
tone, wounds in vaginal wall, and critical cystocele or rectocele among 
other factors [59]. Possible side effects include the possibility of 
urinary tract infections (UTIs) [59]. Today, diaphragms and cervical 
caps have been overshadowed by oral contraceptives. They are only 
used by a small population of women, and currently are experiencing 
low approval among women [63].
Female condom
The female condom is a barrier contraceptive that functions 
similarly to a male condom. However, it is worn by the female partner 
internally rather than the external covering of the male condom. The 
main function of this contraceptive method is to protect against 
pregnancy and sexually transmitted diseases. It creates a physical 
separation between the genitals using a polyurethane material, 
Figure 8: Birth control sponge [52].
Figure 9: Diaphragm [61].
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visualized in Figure 10 [64].
The female condom has two flexible rings at the end, one which 
is used to insert the condom inside the vagina, and the other which 
covers the outer parts of the external genitalia [64]. This product 
was created was to give women more control over the prevention 
of STDs [66]. A man might refuse to wear a condom but by using 
this, the female can protect herself accordingly. Moreover, this 
method of contraception allows for insertion prior to intercourse 
without disrupting sexual activity [67]. Even though this method of 
contraception is not used as commonly as the male condom, it is still 
just as available and offers the same or better protection than its male 
counterpart.
The female condom offers some benefits over the male condom. 
Providing women with a condom suited to their anatomy increases 
the control women have over their health [67]. The polyurethane 
material is thicker and is less susceptible to forming holes than latex 
[64]. It is also a great alternative for those who might have a latex 
allergy. In terms of protection provided, studies suggest that the 
female condom is just as protective as the male condom, if not more 
so. The female condom can reduce the risk of women getting HIV by 
90% [68].
Female condoms are readily available to obtain for anyone of 
any age or gender. These condoms are found at local drugstores in 
the United States (US), without a prescription, for approximately $6 
(USD) for a box of eight depending geographic location in the US. No 
identification is required to buy this contraceptive method, thus age is 
not a restriction in obtaining them. Moreover, the female condom is 
provided via Medicare for beneficiaries in 32 states [66]. They are also 
available at some family planning centers or local health centers, such 
as a Planned Parenthood health center free of charge.
Spermicide
Spermicides are chemical agents that disrupt the sperm cell 
membrane, decrease sperm motility and eventually destroys 
the sperm. The most commonly used spermicides include N-9 
methoxy polyoxyethylene glycol 55 laurate, and p-methyl phenyl 
polyoxyethylene [59]. Spermicides come in various forms including 
cream, foam, soluble film, jelly, tablet, and suppositories. This method 
of contraception commonly supplements other methods such as 
diaphragms and cervical caps among others. Research shows that the 
resulting rate of pregnancy with spermicide use is 6 to 18% compared 
with 26 to 28% with just the conventional barrier method. However, 
the efficiency of spermicides is increased when used with barrier 
devices like diaphragms and cervical caps as previously discussed. 
Possible reasons for mechanism failure include reduced contact times 
between the semen and spermicide. Other reasons include the failure 
of spermicide distribution [63].
Due to their availability, spermicides are a common method of 
contraception around the world. Typically, spermicides should be 
left on for 6 to 8 hours after intercourse in order to work efficiently 
[69]. The application of spermicides varies depending on the 
specific spermicide being utilized. If the spermicide is being used as 
a supplement contraceptive it is typically recommended to situate 
the barrier contraceptive with the spermicide in a way that it covers 
the cervix. In a scenario in which a woman is utilizing a spermicide 
delivered as foam, intercourse has to take place instantly after 
application. If a woman is utilizing jellies and creams the wait time 
for intercourse should be 2 to 3 minutes after application. In dealing 
with suppositories and foaming tablets the wait time for intercourse 
should be  3-15  minutes after the application of the spermicide. 
Finally, when dealing with soluble films the wait time for intercourse 
should be 30 minutes and these times should not be exceeded [59].
Studies show that women who utilize diaphragms supplemented 
by spermicides have a higher possibility of acquiring a urinary tract 
infection (UTI). Some of the adverse reactions include a higher risk 
UTIs in women that use spermicides as a form of contraception than 
women that apply distinct contraception methods. Patients that are 
pregnant or plan to get pregnant are advised against spermicides 
due to the unfavorable effects including spontaneous abortions and 
development of Down syndrome [70].
Natural planning or fertility awareness
Contraceptive methods based on fertility awareness are those 
methods that involve the identification of monthly fertility patterns 
in women. Natural awareness methods predict women’ s fertility 
by identifying physical signs and symptoms, such as cervical 
secretions and basal body temperature, which change with hormonal 
fluctuations during the menstrual cycle [71]. Women who do not 
want a pregnancy practice sexual abstinence during the days of the 
month in which they are fertile. Usually, women who choose natural 
planning or fertility awareness as a contraceptive method fall between 
the ages of 19 and 29 years old.
Fertility awareness-based methods are performed monthly during 
the menstrual cycle. The method is highly effective as long as women 
avoid having sex during days of ovulation/fertile days [71]. These 
methods are noninvasive and do not require medical procedures 
performed by a physician. Fertility  awareness-based  methods of 
contraception are fully reversible. They can be conversely used as a 
pregnancy method by engaging in sexual activity during the fertile 
days of the menstrual cycle [72].
Contraindications include physical separation and lack of support 
from male partners that contribute to the failure or discontinuation 
of fertility awareness-based methods. Unless women have adequate 
communication, respect from their parents, deeper intimacy, and a 
working understanding of the reduced frequency of sexual intercourse 
involved with this method, then fertility  awareness-based  methods 
are contraindicated [72]. One of the benefits of this fertility awareness 
method is its low cost.
Tubal ligation
Tubal ligation, a method of female sterilization, is a type of 
permanent birth control by which a woman has her fallopian tubestied, 
Figure 10: Female condom [65].
Austin J Reprod Med Infertil 4(2): id1049 (2017)  - Page - 011
Persaud-Sharma D Austin Publishing Group
Submit your Manuscript | www.austinpublishinggroup.com
closed, or cut to prevent a pregnancy. The procedure is intended to 
block the passage of eggs from the ovaries into the fallopian tubes, 
where they could be fertilized by sperm [73]. Though available since 
the early 1900s, it was not until the 1960s when cultural changes 
increased the popularity of female contraception and millions of 
women had more access to sterilization procedures, such as tubal 
ligation, when insurance companies decided to cover them [73].
Tubal ligation is more common among women who belong to 
minority groups, and those who have lower income and education 
levels [74]. Similar to other permanent methods of contraception, 
tubal ligation tends to be more common in older women and 
women who already have children. About 700,000 tubal ligations 
are performed in the United States each year, with approximately 
eleven million US women relying on it as their primary method of 
contraception [75]. This is a highly effective method of permanent 
contraception; however, it is not one hundred percent effective. One 
year after the procedure, five out of one thousand women (0.5%) have 
a risk of becoming pregnant. Five years after the procedure, around 
thirteen out of a thousand women (1.3%) may have become pregnant 
[75].
Tubal ligation is a surgical procedure which blocks, ties, or cuts 
the fallopian tubes. It can be done by laparoscopy in which a viewing 
and a surgical instrument are inserted through two small incisions in 
the abdomen. Tubal ligations performed after childbirth is performed 
via mini-laparotomy within 36 hours of the baby being delivered [75].
Ligation can also be accomplished with the use of tubal implants. 
These implants are small metal springs inserted in the fallopian 
tubes in a nonsurgical procedure that only requires local anesthesia 
or oral analgesics [76]. The cervix is first dilated and then a catheter 
that places the implant passes through the cervix into the uterus 
and into the fallopian tubes. An X-ray  is taken after the procedure 
to assure that the implants were placed correctly and that the tubes 
are closed [76]. When tubal implants, such as Essure, are used, the 
sterilization is not immediately effective which forces women to use 
additional contraception for another three months until permanent 
tubal ligation occlusion is verified [76]. Both surgical and nonsurgical 
methods of tubal ligation are performed by a gynecologist or general 
surgeon.
Depending on the age of the patient, the method of tubal ligation, 
and the overall health of the reproductive organs, tubal ligation 
reversal– or tubal anastomosis– is possible. Tubal ligation reversal is 
done by laparoscopy in which the surgeon unties the tubes or removes 
any implants that block them [77]. The surgeon then proceeds to 
reconnect the ends of the tubes to the uterus. When compared 
to in vitro fertilization (IVF) procedures, tubal ligation reversal was 
the most cost-effective method for women less than 41 years of age 
who desired to become pregnant after a previous tubal ligation [77]. 
For women older than 41, the success rate of pregnancy after tubal 
ligation was higher with the use of IVF than by tubal ligation reversal.
Complications stemming from tubal ligation procedures are 
uncommon. However, of the minor complications possible, infection 
and separation of the wounds are the most likely. Major complications 
that could occur are severe blood loss, anesthesia-related problems, 
need for a larger incision during surgery, and perforation of organs 
when the laparoscope is inserted into the abdominal cavity. Risks 
associated with the surgery tend to increase when women suffer 
from other conditions, such as diabetes, obesity, or cardiovascular 
problems.
In the event that tubal ligation is not effective, a pregnancy is likely 
to occur, with an increased risk of ectopic pregnancy [78]. Ectopic 
pregnancies happen when a fertilized egg implants in the fallopian 
tubes or other regions of the abdomen rather than in the uterus. 
This condition requires emergency treatment. Symptoms of ectopic 
pregnancies include nausea, vomiting, abdominal cramps, weakness, 
and pain on one side of the body. An ectopic pregnancy could lead to 
fallopian tube rupture and cause severe pain and bleeding.
The uncertainty of a patient in regards to tubal ligation is a 
contraindication for this type of birth control. The decision to 
perform a tubal ligation should be treated as a permanent, irreversible 
procedure, despite the possibility of a future tubal ligation reversal 
or a pregnancy through in vitro fertilization [78]. The patient should 
ask for the procedure herself, without external pressure, when she is 
in a competent state of mind to make such decisions. Tubal ligation 
performed via laparoscopy is contraindicated in patients suffering 
from diaphragmatic hernias and severe cardiopulmonary diseases 
[73]. Compression of the vena cava diminishes cardiac return, 
leading to cardiac decompensation. Splinting of the diaphragm by 
laparoscopic techniques may also reduce respiratory tidal flow [73]. 
Considerations needs to be given to obese patients in which the 
presence of morbid obesity take laparoscopy out of the list of low- 
risk surgeries when safer procedures are available. For gynecologic 
pathologies, such as ovarian tumors and pelvic relaxation, in which 
hysterectomies are suggested, the use of laparoscopic tubal ligation is 
obviated. The current costs of tubal ligation range from $0 to $6,000 
(USD). The mean cost for the tubal ligation procedure was $5,163 
(USD) among commercially insured women in the United States. 
During a six-month follow-up of 7,286 women who had undergone 
laparoscopic bilateral ligation, the total medical and prescription 
costs were $7,568 (USD) [79].
Tubal ligation has been associated with lower incidence, stage, and 
mortality among women with aggressive endometrial carcinomas. 
Tubal ligation prevents the passage of endometrial carcinoma cells 
from the fallopian tubes into the peritoneum, which seems to be a 
crucial step in the development of endometrial cancer [80]. Tubal 
ligation has also been associated with reduced risk of invasive ovarian 
cancer. The tubal ligation procedure has protective effects that are 
mediated by the ablation or prevention of ovarian seeding by pre- 
cancerous cells from the uterus and fallopian tubes [80].
Transcervical sterilization
Transcervical sterilization is a permanent method of birth 
control. As shown in Figure 11 & 12, a small metal coil is inserted 
into each of the two fallopian tubes [82]. Over the next 3 months, scar 
tissue forms around each of the metal coils and acts as a plug which 
prevents transport and fertilization of eggs [83].
Sterilization does not protect against sexually transmitted 
infections, so a method of STI prevention should be used in addition 
to this procedure. The first transcervical sterilization method was 
approved in the United States in 2002 [85]. It is the second most 
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commonly used contraceptive method for women between the ages 
of 15-44 and has been used by approximately 9.4 million women in 
the United States [86].
Sterilizations can be performed either laparoscopically through 
a small set of incisions made in the abdomen, or hysteroscopically 
through a tube that is inserted through the vagina that allows for 
visualization of the uterus [87]. Progress has been made to replace 
minimally invasive techniques with even less invasive techniques that 
can be performed using only anesthesia to numb the affected area 
and without the need for incision [88]. The hysteroscopic procedure 
is considered to be a  one-day  procedure in which the woman can 
return to her normal activities within the same day of treatment 
[82]. Sterilization is a permanent me t ho d of birth control and is 
not reversible. However, other methods of birth control should be 
used in the three months following application while the scar tissue 
takes its time to form and plug the fallopian tube [87]. Women may 
experience some discomfort during or after the procedure such as 
pain, dizziness, nausea, or light bleeding.
Approximately 8% of first attempts at placing the insert are 
unsuccessful [89]. If the fallopian tube is not completely blocked 
off, due to misplacement, additional birth control methods should 
be used to prevent pregnancy [90]. Once a healthcare provider 
confirms that the fallopian tube is completely occluded, transcervical 
sterilization is effective at preventing more than 99% of pregnancies 
[83]. If pregnancy does occur, there is an increased likelihood that 
the pregnancy is ectopic. In the case of injury or continuous pain, the 
Figure 11: Forms of tubal ligation [81].
Figure 12: Insertion of transcervical sterilization coil. a) Applicator handle b) 
Uterus c) Flexible catheter d) Tubal ostium e) Fallopian tube f) Micro-insert 
[84].
device can be removed by a follow-up surgical procedure [90].
Sterilization should not be performed for women that are 
currently pregnant, delivered or terminated pregnancy 6 weeks prior 
to insertion, had a recent pelvic infection, proximal tubal occlusion, 
are currently taking immunosuppressants, or have a malformed 
uterus known as unicornuate uterus [91]. Depending on the facility 
and insurance used, sterilization can cost between $0 and $6,000 
(USD) [92].
Emergency contraception
Emergency contraceptive is a broad, umbrella term for chemical 
contraceptives that can be taken or implanted after unprotected 
sexual intercourse [93]. The way an emergency contraceptive works is 
in prevention of the fertilization of an egg by a sperm even after sexual 
intercourse. It is used only as a method to prevent pregnancy, not to 
prevent the transmission of sexually transmitted diseases [94]. The 
benefit of this contraceptive method is to prevent pregnancy from 
outside sources such as the failure of another contraceptive method, 
partner refusal, or other sexual assault, among others. There are two 
main types of emergency contraceptives: the morning-after pill and 
copper IUD.
The  morning-after  pill lowers the chances of pregnancy but is 
less effective than OCPs. This pill estimates a range of effectiveness 
between 52% and 94% in reducing pregnancy risk [95]. Under this 
category there are two pills that are the most widely used- Ella and 
Plan B. The Ella pill is most effective and can be used up to 5 days after 
unprotected sex, but requires a prescription. It works by preventing 
ovulation, even during the time in your cycle when a woman is most 
fertile, for five full days following unprotected sex [96]. The Plan-B pill 
is not as effective and can be used up to 5 days after unprotected 
intercourse, but works better the earlier it is used. However, unlike 
Ella, no prescription is needed. Plan-B works by stopping the release 
of an egg from the ovary and by preventing fertilization of the egg 
[97]. For both pills, there are several side effects such as headaches 
and nausea, but few users have demonstrated serious adverse effects 
[97].
The copper IUD is a copper-releasing device that is placed in the 
uterus and is used to prevent a pregnancy. It can be placed up to five 
days after having unprotected sex. It has an effectiveness of 99% after 
placement for the next ten years [98]. Using a copper IUD, however, 
does have side effects, namely a longer and heavier period for several 
months a n d increased possibility of pelvic inflammatory disease 
[98]. This method requires a prescription by a health care provider. 
Using a copper IUD requires removal prior to attempting becoming 
pregnant.
Ethical Considerations
State laws
The Patient Protection and Affordable Care Act of 2010 commonly 
referred to as Obamacare or the ACA is a federal law that has set a 
standard of health care coverage for nationwide insurance companies. 
A key provision of this law pertaining to reproductive health requires 
that counseling or educational services and contraceptive methods 
including diaphragms, sponges, birth control pills, vaginal rings, 
IUDs, emergency contraception, and sterilization are covered at no 
additional cost, without a copayment or coinsurance [99].
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Some state laws have been revised to match or expand the 
requirements outlined by the ACA. For instance, three states-
California, Illinois, and Vermont-now mandate insurance coverage 
of over  -the-counter  contraceptive methods although they may 
require a valid prescription [100]. In addition, many states including 
California, District of Columbia, Hawaii, Illinois, Oregon, and 
Vermont have expanded the ACA requirements to cover an extended 
supply of contraceptive methods. An extended supply would mean 
that enough treatment f or one year is provided during one visit 
[100]. Despite recent attempts to repeal the ACA, some states like 
Virginia have made strides towards protecting coverage of female 
contraceptives by introducing state laws that will explicitly continue 
coverage even without the ACA [101].
Minors and consent laws
Consent laws outline the age and conditions at which one is able to 
agree to contraceptive treatments, testing and treatment for sexually 
transmitted infections, prenatal care, abortion services, adoption 
services, prenatal healthcare, and healthcare for the minor’s child 
[102]. A majority of states, in addition to the District of Columbia, 
allow minors as young as 12 years old to consent to contraceptive 
treatments given that they meet the state’s criteria as previously 
mentioned. However, Alabama, Hawaii and Pennsylvania only 
allow minors of 14 years of age or older to consent to such services 
[103]. All minors, women under the age of 17, are allowed access 
to testing and treatment for sexually transmitted infections [102]. 
Each state differs in their policies that explicitly allow for minors 
to consent to contraceptive services. Some states can allow for all 
minors to consent while other states require that other criteria be met 
including: minimum age, current parenthood, current pregnancy or 
previously pregnancy, high school graduation, maturity, or physician 
determination that the minor’s health is at risk.
Currently, there are 25 states that require circumstances to be met 
in order for minors to be eligible to manage their use of contraceptive 
services without guardian involvement. For instance, restrictive state 
policies can be found in states like Connecticut, Indiana, Michigan, 
or Vermont in which minors can only can consent if they are married 
[103]. A total of 21 states, in addition to the District of Columbia, 
allow all minors to consent. Of those 22 locations, states such as 
Kentucky, Maryland, Minnesota, Montana, and Oregon provide 
physicians the choice to inform the minor’s parents. However states 
such as Massachusetts, New York, and Wyoming provide confidential 
services, meaning that the minor’s health care decisions are kept 
private. There are 4 states - North Dakota, Ohio, Rhode Island, and 
Wisconsin - that currently do not have explicit policies about minor 
consent [103].
Contraceptive methods are typically equally effective for women 
of all ages. However, age, alongside potential desire of children 
in the future, is an important factor considered when determining 
an appropriate method, especially for irreversible contraceptive 
treatments.
Rape/Incest
Rape is understood to be  non-consensual  sexual intercourse 
between two people. However, in the United States the age of sexual 
consent varies from 16-18 years old depending on the state [104].
Accordingly, it is illegal for anyone to have a sexual encounter 
with anyone under 16-18 years old depending on the state, though 
exceptions may apply when the person is married or if the other 
party is a minor and the sexual activity is consensual [105]. Studies 
have indicated that at least half of children born to female minors 
are fathered by adult men, also known as statutory rape [106]. One 
method to empower women to have more control in unequal sexual 
relationship is to increase their access to and the availability of 
emergency contraceptives. There have been some cases in which rape 
victims were not allowed to be prescribed emergency contraceptives 
[107]. However, now with the establishment of federal and state rape 
laws, all states provide necessary care for rape victims [108].
Incest is usually defined as sexual intercourse between members 
of an immediate family. This includes between a father and his child, 
a mother and her child, or siblings [109]. Different states, however, 
have different laws defining incest and how it is to be addressed in a 
court of law. These definitions of incest can include sexual intercourse 
between stepfamilies - such as a stepfather with his stepdaughter. 
Rape and incest can be closely affiliated and often  co-occur  if one 
party is a minor and cannot consent. Similar to rape laws, if a person 
experiences incest, all states provide emergency contraceptives or 
abortion methods in order to avoid unwanted pregnancy [108].
Ethical case example
Contraception has been an area of discussion and debate in the 
world of ethics and medicine. Many religious backers do not find it 
moral for people to use contraceptive methods because it prohibits 
a life from forming that some higher power might have desired 
wanted that life to be born. Notably, in the Zubik v. Burwell case from 
2016, some employer’s insurance users are looking for an insurance 
company that will not provide contraceptive coverage because of 
their religious beliefs and ideologies [110]. Moreover, another big 
issue with the field of contraceptives is the ambiguity with how 
exactly these contraceptives work [111]. Push back from the FDA 
with approval of pills such as Ella or Plan B were once a very big issue 
for anyone who might be taking these emergency contraceptives but 
they have now been cleared and allowed to be used by the general 
public.
Conclusion
Currently, the most common methods of contraception used in the 
United States are combined oral contraceptives, female sterilization, 
the male condom, and IUDs, respectively. In recent years, the use of 
IUDs has increased as the lack of evidence of association with their use 
and PID has been widely disseminated. However, despite the increase 
in utilization of female contraceptive methods, tremendous tumult 
exists surrounding the discussion of a woman’s right to reproductive 
freedom. Though outside of the scope of this discussion, it remains 
of critical importance that women are able to obtain the information 
necessary to learn more about each method, its proper use and the 
statistics regarding its efficacy. The preceding discussion outlined the 
use of sixteen FDA approved contraceptive methods in addition to 
an ethical consideration of the issues of contraception in the United 
States. The provided Summary Table 1 is intended to be used as a 
quick reference tool for both students and those looking to compare 
methods for personal use. The information provided above does not 
substitute for the judgment of a trained medical professional.
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